COVID-19阳性患者CT检查中肝脂肪变性发生率更高
回顾性研究纳入316例患者(204例RT-PCR阳性,112例RT-PCR阴性且胸部CT阴性),在胸部CT右肝叶放置单ROI测量肝衰减值≤40 HU定义脂肪变性。RT-PCR阳性组肝脂肪变性频率31.9% vs 对照组7.1%(p<0.001),校正年龄和性别后OR 4.698(95%CI 2.12-10.41,p<0.001)。
要点
- COVID-19阳性患者胸部CT偶然检出肝脂肪变性频率为31.9%,高于对照组的7.1%
- 肝衰减值≤40 HU(右肝叶VI-VII段单ROI)可定义肝脂肪变性
- 校正年龄和性别后,COVID-19阳性组脂肪变性OR为4.698(95%CI 2.12-10.41)
核心结论
- COVID-19阳性个体中肝脂肪变性患病率显著更高,与近期 linking 肥胖和COVID-19感染的研究一致,肝脂肪变性、代谢综合征和肥胖之间存在复杂关系。
- 需要进一步研究确认在考虑多种变量后该关联是否仍然存在,以及与疾病严重程度和最差临床结局的可能关系。
研究设计与样本
- 回顾性研究,共316例患者,其中204例RT-PCR阳性,112例RT-PCR阴性且胸部CT阴性。
- 在胸部CT右肝叶VI-VII段放置单个ROI测量肝衰减值,以肝衰减值≤40 HU定义脂肪变性。
关键影像表现/征象
- 胸部CT右肝叶VI-VII段单ROI测量肝衰减值≤40 HU定义为肝脂肪变性。
诊断标准与关键数值
- 肝脂肪变性定义为肝衰减值≤40 HU(右肝叶VI-VII段单ROI测量)。
- RT-PCR阳性组肝脂肪变性频率31.9% vs 对照组7.1%(p<0.001)。
- 校正年龄和性别后,COVID-19阳性组脂肪变性OR 4.698(95%CI 2.12-10.41,p<0.001)。
临床应用与阅片要点
- 胸部CT阅片时可关注右肝叶VI-VII段肝衰减值,肝衰减值≤40 HU提示肝脂肪变性。
局限性
- 需要进一步研究确认在考虑多种变量后该关联是否仍然存在,以及与疾病严重程度和最差临床结局的可能关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Recent studies have demonstrated that obesity is significantly associated with increased disease severity, hospitalizations and mortality in COVID-19, with a potential role in the pathogenesis and prevalence in the new pandemic. The association with hepatic steatosis, however, a condition closely related to obesity within the spectrum of systemic metabolic dysfunctions, remains to be elucidated. We aimed to evaluate the frequency of hepatic steatosis as incidentally detected in chest CT examinations of COVID-19 positive patients in comparison to non-infected controls.
METHODS: A retrospective study was performed with 316 patients (204 RT-PCR positive; 112 RT-PCR negative and chest CT negative). Steatosis was measured with placement of a single ROI in the right lobe of the liver (segments VI-VII) and defined as a liver attenuation value ≤ 40 HU.
RESULTS: The frequency of hepatic steatosis was higher in the RT-PCR positive group in comparison to controls (31.9% vs. 7.1%, p < 0.001). Logistic linear regression analysis showed a 4.7 times odds of steatosis in the COVID-19 positive group as compared to controls after adjusting for age and sex (OR 4.698; 95% IC 2.12-10.41, p < 0.001).
CONCLUSION: A significantly higher prevalence of steatosis was found among COVID-19 positive individuals. These findings are in accordance with other recent studies linking obesity and COVID-19 infection, as there is an intricate relationship between liver steatosis, metabolic syndrome and obesity. Further studies are required to confirm if such association remains after accounting for multiple variables, as well as possible relationships with disease severity and worst clinical outcomes.
引用
- Medeiros AK, Barbisan CC, Cruz IR, et al. Higher frequency of hepatic steatosis at CT among COVID-19-positive patients. Abdom Radiol (NY). 2020. PMID: 32683613. doi:10.1007/s00261-020-02648-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。